Selecta Biosciences (SELB) Tops Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 2, 2023 7:30 AM EST- Topline data for Phase 3 DISSOLVE I & II clinical trials of SEL-212 in chronic refractory gout remains on track for Q1 2023 -
- Continue to enroll patients in ReiMMAgine, the Phase 1/2 clinical trial of SEL-302 for the treatment of methylmalonic acidemia (MMA)Â -
- IND enabling studies expected to commence in 2023 for interleukin-2 (IL-2) candidate to be studied in combination with ImmTOR, as well as IgA protease candidate for the treatment of IgA Nephropathy -
- As of December 31, 2022, Selecta... More
